Technology | May 27, 2014

IBA Introduces Compass QuickCheck Functionality for Safer, More Efficient Cancer Treatment

Accidental linac dose delivery deviations detected easily with pass/fail indication

IBA Compass 3.1 QuickCheck QA System Radiation Therapy Treatment Planning

May 27, 2014 — IBA (Ion Beam Applications S.A.) announced the release of Compass 3.1 with the new Compass QuickCheck feature. Compass QuickCheck allows for fully automated gamma analysis in just one look, and automatic pass/fail is instantly indicated based on customers’ protocol thereby replacing human subjectivity. Compass now offers more efficiency and full workflow flexibility, allowing physicists and dosimetrists to choose the most efficient QA for any clinical need, whether measurement or calculation based.

“Compass is used to verify every IMRT and VMAT plan fast with 3-D computations. A huge advantage compared to other patient QA systems is the possibility of optionally conducting dose reconstructions based on MatriXX measurement,” said Mark P. Arends and Alle H. Ausma, medical physicists at Radiotherapy Institute Friesland, Leeuwarden, Netherlands. “Accidental linac dose delivery deviations from the treatment plan can be detected. The user can specify his own criteria for selecting the desired detection level. With the implemented 2-D QuickCheck, module deviations between expected and measured chamber response result automatically in a pass or fail indication.”

With its powerful Collapsed Cone Algorithm for independent dose calculations, Compass allows TPS-class dose calculations on real patient computed tomography (CT), real patient CT-based DVH, and global and local 3-D Gamma. Additionally, independent beam modeling of individual linacs enables flexibility in precisely modeling as many machines as needed for highly accurate plan verifications. Physicists can measure and compare real linac delivery vs. TPS-planned delivery as well as analyze the effect of segment errors on the total treatment accuracy.

“We are pleased to release the newest version of Compass with the new Compass QuickCheck, which offers significant efficiency that we feel is the most robust patient plan verification system available today. We are confident that this newest version of Compass is a huge step forward in the field of plan verification and provides safer radiation therapy,” remarked Ralf Schira, vice president of marketing for IBA Dosimetry.

For more information:

Related Content

IBA Releases Razor Nano Ionization Chamber
News | Proton Therapy | September 22, 2017
September 22, 2017 — IBA (Ion Beam Applications S.A.) announced the release of the Razor Nano Chamber, the smallest a
Penn Medicine Treats World's First Patient on Varian's Halcyon System
News | Radiation Therapy | September 22, 2017
September 22, 2017 — Varian Medical Systems announced a patient at Penn Medicine, with head & neck cancer, became
BrainLAB Announces FDA Clearance For Two New Indication-Specific Radiosurgery Software Applications
Technology | Treatment Planning | September 21, 2017
Brainlab announced that it has received U.S. Food and Drug Administration (FDA) clearance for Elements Spine SRS and...
Accuray Showcases CyberKnife and Radixact Systems at ASTRO 2017
News | Radiation Therapy | September 21, 2017
Accuray Inc. announced that data and first-hand experience with its advanced CyberKnife and Radixact Systems will be...
RayCare Oncology Information System Being Shown at ASTRO 2017
News | Radiation Therapy | September 20, 2017
RaySearch will be exhibiting its next-generation oncology information system (OIS) RayCare, among other highlights, at...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Overlay Init